News
Mission drives innovation, and innovation improves quality of life
News
-
TargetRx was awarded the "2021 China's Top 100 Pharmaceutical R&D Strength Series"2021-09-26 Views:62
"2021 China s Top 100 Pharmaceutical R&D Strength Series " is evaluated by the YAOZHI com, the committee of China Pharmaceutical R&D-Summit Organizing Committee and China Pharmaceutical, referring to the R&D-related data...
-
TargetRx announces dosing of first subject in phase I clinical trial of TGRX-326, a next-generation ALK inhibitor for non-small cell lung cancer2021-07-01 Views:99
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx) announced that the first subject has been dosed with the ALK ROS1 inhibitor TGRX-326, a Class 1 innovative new drug for treatment of non-small cell lung cancer, in (First-in-Human) ... -
TargetRx announces dosing of first subject in first-in-human phase I clinical trial of TGRX-678, an allosteric BCR-ABL inhibitor with novel mechanism against chronic myelogenous leukemia2021-06-24 Views:138
Recently, Shenzhen TargetRx Inc (hereinafter referred to as TargetRx), a leader in small molecule targeted drugs, announced that the first subject has been dosed in the first-in-human clinical trial of its allosteric Bcr-Abl inhibitor TGRX-678 with a new... -
Clinical Trial Recruitment | Patient Recruitment for Clinical Study of TargetRx's third-generation ALK inhibitor TGRX-326 for NSCLC2021-03-15 Views:50
A phase I dose-escalation and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of TGRX-326 in patients with ALK-positive or ROS1-positive advanced non-small cell lung cancer... -
Year-end Summary | TargetRx won multiple awards in 20202020-12-31 Views:42
The year 2020 is a very rewarding year, in which, the new drugs independently developed by TargetRx made breakthrough progress: the next-generation Bcr-Abl inhibitor TGRX-678 for treatment of CML and the ALK ROS1 dual inhibitor TGRX-326 for treatment of... -
TargetRx's next-generation ALK inhibitor for NSCLC has been cleared for clinical trials in China2020-12-17 Views:30
On December 17, 2020, TGRX-326, a next-generation ALK ROS1 dual inhibitor independently developed by Shenzhen TargetRx Inc , has officially obtained the clinical trial notification issued by the Center for Drug Evaluation (CDE)...
Tel: +86-0755-86934300
Rm 301, Building A1, Kexing Science Park, No. 15 Keyuan Rd., Nanshan District, Shenzhen, China
E-mail: targetrx@tjrbiosciences.com